CN110769815A - 口服的卡利拉嗪固体制剂 - Google Patents

口服的卡利拉嗪固体制剂 Download PDF

Info

Publication number
CN110769815A
CN110769815A CN201880040070.6A CN201880040070A CN110769815A CN 110769815 A CN110769815 A CN 110769815A CN 201880040070 A CN201880040070 A CN 201880040070A CN 110769815 A CN110769815 A CN 110769815A
Authority
CN
China
Prior art keywords
pharmaceutical composition
cariprazine
composition according
treatment
solid pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880040070.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·康塔
E·萨巴
T·B·达罗克兹
Z·玛格斯
R·拉兹基纳拉伯斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gerry Factory
Original Assignee
Gerry Factory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerry Factory filed Critical Gerry Factory
Publication of CN110769815A publication Critical patent/CN110769815A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880040070.6A 2017-06-13 2018-06-12 口服的卡利拉嗪固体制剂 Pending CN110769815A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1700253 2017-06-13
HUP1700253 HUP1700253A1 (hu) 2017-06-13 2017-06-13 Szilárd orális gyógyszerkészítmények
PCT/IB2018/054227 WO2018229641A1 (en) 2017-06-13 2018-06-12 Solid preparation of cariprazine for oral administration

Publications (1)

Publication Number Publication Date
CN110769815A true CN110769815A (zh) 2020-02-07

Family

ID=89992469

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040070.6A Pending CN110769815A (zh) 2017-06-13 2018-06-12 口服的卡利拉嗪固体制剂

Country Status (20)

Country Link
US (1) US20200222391A1 (https=)
EP (1) EP3638210A1 (https=)
JP (1) JP2020523335A (https=)
KR (1) KR20200016378A (https=)
CN (1) CN110769815A (https=)
AR (1) AR112137A1 (https=)
AU (1) AU2018284138A1 (https=)
BR (1) BR112019025214A2 (https=)
CA (1) CA3064694A1 (https=)
CL (1) CL2019003619A1 (https=)
CO (1) CO2020000168A2 (https=)
EA (1) EA202090029A1 (https=)
HU (1) HUP1700253A1 (https=)
IL (1) IL271108A (https=)
MX (1) MX2019015206A (https=)
PE (1) PE20200334A1 (https=)
PH (1) PH12019502566A1 (https=)
TW (1) TW201906608A (https=)
WO (1) WO2018229641A1 (https=)
ZA (1) ZA201908454B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114681406A (zh) * 2020-12-25 2022-07-01 上海京新生物医药有限公司 一种卡利拉嗪长效缓释微球及其制备方法
CN114748428A (zh) * 2020-12-25 2022-07-15 上海京新生物医药有限公司 一种高载药量的盐酸卡利拉嗪长效缓释微球及其制备方法
WO2023160583A1 (zh) * 2022-02-22 2023-08-31 上海云晟研新生物科技有限公司 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2317852T3 (pl) 2008-07-16 2015-05-29 Richter Gedeon Nyrt Preparaty farmaceutyczne zawierające ligandy receptora dopaminy
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11344503B2 (en) * 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations
EP4206191B1 (en) * 2020-08-26 2025-12-17 Shanghai Aurora Biotechnology Co., Ltd. Pharmaceutically acceptable salt of cariprazine and crystal form thereof, and preparation method therefor and use thereof
IL315074A (en) 2022-03-17 2024-10-01 Mapi Pharma Ltd Storage systems containing cryprazine or its salts
HU231682B1 (hu) * 2022-08-05 2025-10-28 Richter Gedeon Nyrt. Kariprazin tartalmú szájban diszpergálódó tabletta

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102118970A (zh) * 2008-07-16 2011-07-06 吉瑞工厂 包含多巴胺受体配体的药物制剂
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
CN106692149A (zh) * 2015-11-13 2017-05-24 天津市汉康医药生物技术有限公司 一种卡利拉嗪药物口服制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6248618A (ja) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk 徐放性製剤およびその製造法
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
CN101815519B (zh) * 2007-08-03 2013-08-21 吉瑞工厂 包含多巴胺受体配体的药物组合物和使用多巴胺受体配体的治疗方法
KR101563383B1 (ko) 2008-02-21 2015-10-26 미쓰비시 타나베 파마 코퍼레이션 경구 투여용 고형 제제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102118970A (zh) * 2008-07-16 2011-07-06 吉瑞工厂 包含多巴胺受体配体的药物制剂
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
CN106692149A (zh) * 2015-11-13 2017-05-24 天津市汉康医药生物技术有限公司 一种卡利拉嗪药物口服制剂及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
无: "Cariprazine: Comparison of Slow- and Immediate-release Forms", 《网页：HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/NCT02165098》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114681406A (zh) * 2020-12-25 2022-07-01 上海京新生物医药有限公司 一种卡利拉嗪长效缓释微球及其制备方法
CN114748428A (zh) * 2020-12-25 2022-07-15 上海京新生物医药有限公司 一种高载药量的盐酸卡利拉嗪长效缓释微球及其制备方法
CN114748428B (zh) * 2020-12-25 2023-05-23 上海京新生物医药有限公司 一种高载药量的盐酸卡利拉嗪长效缓释微球及其制备方法
CN114681406B (zh) * 2020-12-25 2023-10-13 上海京新生物医药有限公司 一种卡利拉嗪长效缓释微球及其制备方法
WO2023160583A1 (zh) * 2022-02-22 2023-08-31 上海云晟研新生物科技有限公司 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途

Also Published As

Publication number Publication date
TW201906608A (zh) 2019-02-16
CL2019003619A1 (es) 2020-05-15
PE20200334A1 (es) 2020-02-14
PH12019502566A1 (en) 2020-07-20
EA202090029A1 (ru) 2020-03-26
AU2018284138A1 (en) 2020-01-16
WO2018229641A1 (en) 2018-12-20
BR112019025214A2 (pt) 2020-06-16
CA3064694A1 (en) 2018-12-20
EP3638210A1 (en) 2020-04-22
CO2020000168A2 (es) 2021-06-21
HUP1700253A1 (hu) 2019-01-28
AR112137A1 (es) 2019-09-25
ZA201908454B (en) 2021-10-27
IL271108A (en) 2020-01-30
JP2020523335A (ja) 2020-08-06
KR20200016378A (ko) 2020-02-14
MX2019015206A (es) 2020-02-10
US20200222391A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
CN110769815A (zh) 口服的卡利拉嗪固体制剂
Kotreka et al. Gastroretentive floating drug-delivery systems: a critical review
CN102917697B (zh) 用于高剂量的水溶性和吸湿性药物的控释剂型
JP7034343B2 (ja) 自己調節性の浸透性胃保持性薬物送達システム
KR20190049543A (ko) 붕해가 개선된 경구용 고형 제제 조성물 및 이의 제조 방법
CN105492000B (zh) 延迟释放型半胱胺珠粒调配物，以及其制备及使用方法
EP2405900A2 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
CN107205954A (zh) 特别用于治疗注意力缺陷障碍的方法和组合物
CN105431144A (zh) 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
JP6872135B2 (ja) 最適化高用量メサラジン含有錠剤
WO2016062182A1 (zh) 一种普瑞巴林缓释制剂
CN104755074A (zh) 美金刚的药物组合物
CN108601846A (zh) 粘膜粘附性药学组合物及其制备方法
JP2022179727A (ja) リナクロチドの改変または標的放出製剤
CN107530337A (zh) 治疗方法
KR20080026754A (ko) 생물학적 활성성분을 함유하는 방출 제어형 입자, 및 이의제조방법
CN101132780A (zh) 缓慢释放取代的吡嗪化合物的剂型和方法
KR20180096530A (ko) 이토프리드 염산염을 포함하는 속효성과 지속성을 갖는 약학적 제제
CN101478958A (zh) 包含哌啶烷醇和减充血剂的组合的药物组合物
CN107961225A (zh) 一种普瑞巴林微孔渗透泵片及其制备方法
EP4313014B1 (en) A method for the production of gastroretentive compact matrices for the controlled release of active substances and compact matrices thus obtained
KR20090029255A (ko) 생물학적 활성성분을 함유하는 방출 제어형 입자, 및 이의 제조방법
WO2023089553A1 (en) Controlled release formulations of flavoxate and process for preparation thereof
CN114209668B (zh) 一种盐酸阿夫唑嗪缓释制剂及其制备方法
OA19441A (en) Solid preparation of cariprazine for oral administration.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200207